Last reviewed · How we verify
SPD489
At a glance
| Generic name | SPD489 |
|---|---|
| Also known as | lisdexamfetamine dimesylate, LDX, Vyvanse, Lisdexmfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, LDX |
| Sponsor | Shire |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder (PHASE3)
- Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia (PHASE3)
- Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia (PHASE3)
- SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia (PHASE3)
- Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder (PHASE4)
- Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers (PHASE1)
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study (PHASE3)
- Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |